这里是《21健讯Daily》，欢迎与21世纪经济报道新健康团队共同关注医药健康行业最新事件！ 3月4日，拓新药业公告，公司全资子公司精泉生物于近日正式通过了NSF 173 GMP DI认证，标志着公 司已通过NSF严格的质量与安全审核，符合美国联邦法规针对原料生产企业所制定的良好生产规范要 求。 新诺威：艾美赛珠单抗注射液药物临床试验获批 政策动向 市场监管总局进一步加强特殊医学用途配方食品安全监管 市场监管总局近日修订发布《特殊医学用途配方食品生产许可审查细则（2026版）》。《细则》共7章 43条，从生产场所、设备设施、工艺流程、人员管理、制度管理等方面进行严格要求，主要修订了以下 内容：按照2025版特医食品标准的产品分类，调整细化生产许可品种明细；按照2023版特医食品良好生 产规范，进一步明确作业区环境卫生控制要求和关键设备监控要求；按照新修订的《食品生产经营企业 落实食品安全主体责任监督管理规定》，细化关键人员岗位职责；针对产品适用人群及其过敏风险管理 需求，强化产品过敏风险管控；结合出现的食品安全风险以及储运等最新要求，进一步严格原料管理。 3月起，中药将面临最严监管 3月1日起，《中药生产监督 ...

Investment Rating - The report assigns an "Accumulate" rating to the company [1][6]. Core Insights - The report highlights the strong innovative research and development capabilities of the company, which is entering a harvest period for innovative drugs while establishing an international business development ecosystem with several significant collaborations [2][10]. - The company is expected to achieve a compound annual growth rate (CAGR) in earnings per share (EPS) of 48% from 2025 to 2027, with a target price set at HKD 16.58 [10]. Financial Summary - Total revenue is projected to be RMB 31,450.11 million in 2023, with a slight increase of 1.7% year-on-year. However, a decline of 7.8% is expected in 2024, followed by a gradual recovery in subsequent years [4][11]. - Gross profit is forecasted to be RMB 22,177 million in 2023, with net profit expected to be RMB 5,873 million, reflecting a decrease of 3.6% [4][11]. - The price-to-earnings (P/E) ratio is projected to be 18.26 in 2023, increasing to 24.78 in 2024 before declining to 16.80 in 2025 [4][11]. Pipeline Overview - The company has a leading position in the oncology pipeline, with SYS6010 being the fastest progressing EGFR ADC globally, and multiple early-stage assets expected to report data in 2026 [10][14]. - In the weight loss and metabolic fields, the company has established a leading position domestically, with a strategic collaboration with AstraZeneca to develop innovative long-acting peptide drugs [10][24]. - The company has secured a total deal value of USD 18.5 billion from collaborations, including upfront payments and potential milestone payments [10][24]. Clinical Development - The report outlines several key clinical trials, including SYS6010, which is in Phase III for EGFRm NSCLC, and various other assets in different stages of development [18][20]. - The company is actively recruiting for multiple trials, with significant data expected to be released in 2026 [18][20]. Market Position - The company is positioned as a leader in the domestic market for small nucleic acid technology, with a strong pipeline in siRNA [10][24]. - The report emphasizes the company's competitive edge in the next-generation weight loss drugs and cardiovascular metabolic therapies, supported by strategic partnerships with multinational corporations [10][24].

Investment Rating - The report assigns an "Accumulate" rating to the company [1][6]. Core Insights - The report highlights the strong innovation and R&D capabilities of the company, which is entering a harvest period for innovative drugs and has established an international business development ecosystem with several significant licensing agreements [2][10]. - The company is expected to achieve a significant increase in EPS from 0.37 in 2024 to 0.75 in 2025, with a projected growth rate of 48% [10]. - The target price for the company is set at 16.58 HKD, reflecting a favorable valuation based on comparable company analysis [10]. Financial Summary - Total revenue is projected to be 31,450.11 million RMB in 2023, with a slight increase of 1.7% [4]. - Net profit is expected to decrease by 3.6% in 2023, followed by a significant recovery of 47.5% in 2025 [4]. - The company’s PE ratio is forecasted to decrease from 18.26 in 2023 to 12.34 in 2026, indicating an improving valuation over time [4]. Pipeline Overview - The company has a leading position in the oncology pipeline, particularly with SYS6010, which is the fastest progressing EGFR ADC globally, with multiple early-stage assets expected to report data in 2026 [10][16]. - In the weight loss and metabolic areas, the company has established a leading position domestically and has signed a strategic collaboration with AstraZeneca for the development of innovative long-acting peptide drugs [10][24]. - The company has a robust pipeline in the small nucleic acid technology sector, positioning it as a leader in the domestic siRNA market [10][24]. Business Development and International Strategy - The company is making steady progress in its international strategy, with ongoing collaborations with AstraZeneca and other multinational corporations, reflecting its competitive edge in innovative drug development [10][24]. - The company is expected to continue achieving external licensing agreements, with over 20 innovative drug assets entering clinical stages annually [10][24].

Group 1: Industry Policy Dynamics - Recent active policy developments in the pharmaceutical industry may indirectly impact companies like Boji Pharmaceutical (300404) and other medical research outsourcing firms [1] - The National Health Commission approved a pilot program for internet-based pediatric specialty consultations in Beijing, marking a significant step towards the standardization of internet healthcare and potentially accelerating the online medical service process [1] - The National Medical Products Administration announced support for innovation in the biomanufacturing industry during the 14th Five-Year Plan, with a projected 17% year-on-year increase in the approval of innovative medical devices by 2025 [1] - Jiangsu Province's medical insurance bureau is advancing a policy to separate the budget for innovative drugs, which aims to alleviate budget constraints for hospitals in the first three years of negotiated drug prices [1] Group 2: Company Stock Performance - Boji Pharmaceutical's stock price has been fluctuating, closing at 10.56 yuan on February 13, 2026, down 1.31% for the day, with a trading volume of 70.75 million yuan [2] - Over the past five days (February 9 to 13), the stock experienced a price change of 0.38%, with a high of 10.82 yuan and a low of 10.48 yuan, resulting in a volatility of 3.23% [2] - On February 13, there was a net inflow of 4.217 million yuan from institutional investors, while retail investors showed a net outflow; technical indicators suggest a short-term consolidation phase [2] Group 3: Institutional Insights - Institutional interest in Boji Pharmaceutical is moderate, with recent sentiment being neutral; a report from Xiangcai Securities noted increased activity in the innovative drug supply chain, but the industry still faces pressure from medical insurance controls [3] - Multiple institutions forecast Boji Pharmaceutical's net profit to reach approximately 45 million yuan in 2025, representing a year-on-year growth of 56.38%, with an expected earnings per share of 0.12 yuan; projections for 2026 suggest a net profit of 66 million yuan and potential revenue expansion [3] - The company’s "Semaglutide Injection" project is currently in Phase III clinical trials, but specific timelines for progress remain unclear, necessitating attention to subsequent clinical results and their potential impact on performance [3]

Core Viewpoint - The company anticipates achieving revenue of no less than RMB 2.5 billion and net profit of no less than RMB 150 million for the fiscal year ending December 31, 2025, representing a growth rate of over 30% compared to the previous year [1] Group 1: Financial Performance - The aesthetic medicine business is expected to generate over RMB 1.4 billion in revenue and over RMB 700 million in segment profit, with both metrics showing an annual growth rate exceeding 90%, becoming the primary revenue and profit driver for the company [1] - The innovative drug business is entering a harvest phase, with significant revenue growth from Xuan Zhu Bio and Hui Sheng Bio, and a transition from investment to revenue generation, improving the company's profit structure [1] - The company maintains a robust financial position with ample cash reserves, implementing multiple rounds of share buybacks and successfully spinning off Xuan Zhu Bio, which enhances equity value and alleviates R&D funding pressure [1] Group 2: Aesthetic Medicine Sector - The company has successfully obtained approvals for several self-developed core products, including various injectables and devices, establishing itself as a comprehensive aesthetic medicine enterprise [2] - The market share of the core product, Le Ti Bao botulinum toxin, has increased to nearly 20%, with partnerships exceeding 8,000 medical aesthetic institutions, driving rapid sales growth of newly launched products [2] - The company is advancing its global strategy by signing an investment agreement with Swiss aesthetic company Suisselle, aiming to penetrate the EU market and solidify its long-term growth foundation [2] Group 3: Pharmaceutical R&D Progress - Rapid advancements in pharmaceutical R&D are evident, with Xuan Zhu Bio's ALK inhibitor and CDK4/6 inhibitor receiving market approvals, and Xuan Yue Ning being included in the national medical insurance directory [3] - The company achieved a successful spin-off listing of Xuan Zhu Bio on the Hong Kong Stock Exchange, providing significant equity value gains and easing R&D investment pressures [3] - This strategic move supports the company's focus on high-growth sectors like aesthetic medicine, facilitating a transition to a new phase of high-quality development [3]

Core Viewpoint - The company expects to achieve revenue of no less than RMB 2.5 billion and net profit of no less than RMB 150 million for the fiscal year ending December 31, 2025, representing a year-on-year revenue growth of over 30% [1] Financial Performance Factors - The aesthetic medicine business is projected to achieve revenue exceeding RMB 1.4 billion and segment profit over RMB 700 million, with both revenue and profit growth rates exceeding 90% year-on-year, becoming the largest revenue and profit contributor to the group [2] - The innovative drug business is entering a harvest phase, with significant revenue growth from Xuan Zhu Bio and Hui Sheng Bio, and a transition from investment to revenue generation, improving the group's profit structure [2] - The company maintains a robust financial position with ample cash reserves, implementing multiple rounds of share buybacks and successfully spinning off Xuan Zhu Bio, which enhances equity value and alleviates R&D funding pressure [2] Aesthetic Medicine Segment - The company has successfully obtained approvals for several self-developed core products, including the "Youthful Needle" and "L-Arginine Facial Energy Essence," establishing itself as a comprehensive aesthetic medicine enterprise [3] - The market share of the core product, "Le Ti Bao Botulinum Toxin," has increased to nearly 20%, with partnerships exceeding 8,000 medical aesthetic institutions, driving rapid sales growth of newly launched products [3] - The company is accelerating its global expansion, having signed an investment subscription agreement with Swiss aesthetic company Suisselle, aiming to penetrate the EU market and establish a sustainable growth foundation [3] Pharmaceutical R&D Progress - Rapid advancements in R&D are noted, with Xuan Zhu Bio and Hui Sheng Bio achieving significant milestones, including the approval of ALK inhibitor Xuan Fei Ning and CDK4/6 inhibitor Xuan Yue Ning, with the latter included in the national medical insurance directory [4] - The successful spin-off of Xuan Zhu Bio on the Hong Kong Stock Exchange has provided substantial equity value gains and eased R&D investment pressures, allowing the company to focus resources on high-growth sectors like aesthetic medicine [4]

Core Viewpoint - The company expects to achieve a revenue of no less than RMB 2.5 billion and a net profit of no less than RMB 150 million for the fiscal year ending December 31, 2025, reflecting a growth rate of over 30% compared to the previous year [1] Group 1: Financial Performance - The company's aesthetic medicine business is projected to generate over RMB 1.4 billion in revenue and over RMB 700 million in segment profit, with both metrics showing an annual growth rate exceeding 90% [1] - The innovative drug business is entering a harvest phase, with significant revenue growth from Xuan Bamboo Biotechnology and Hui Sheng Biotechnology, improving the company's profit structure [1] - The company maintains a strong financial position with ample cash reserves, enabling multiple rounds of share buybacks and the successful spin-off of Xuan Bamboo Biotechnology, which alleviates R&D funding pressure [1][4] Group 2: Product Development and Market Position - The company has successfully obtained approvals for several self-developed core products in the aesthetic medicine sector, including various injectables and devices, establishing itself as a comprehensive player in the industry [2] - The market share of the core product, Le Ti Bao botulinum toxin, has increased to nearly 20%, with partnerships extending to over 8,000 aesthetic institutions [2] - The company is accelerating its global expansion, having signed an investment agreement with Swiss aesthetic company Suisselle to introduce its products to the EU market, thereby establishing a closed-loop market presence in Europe and the US [3] Group 3: Future Outlook - The company plans to deepen its strategic focus on aesthetic medicine, with seven products currently in the registration application stage and several others in late clinical phases, ensuring a robust pipeline for future growth [3] - The successful spin-off of Xuan Bamboo Biotechnology in October 2025 is expected to provide significant equity appreciation and support the company's focus on high-growth sectors like aesthetic medicine [4]

Core Viewpoint - Jiuyuan Gene has submitted an IND application for its innovative drug JY54 injection, aimed at weight management for obese or overweight individuals, marking a significant advancement in the metabolic treatment field [2] Group 1: Product Development - JY54 injection is a long-acting insulin analog designed to manage weight, showcasing Jiuyuan Gene's commitment to innovation in metabolic diseases [2] - The product is a dual receptor agonist (DACRAs) that mimics natural insulin mechanisms, offering multiple actions such as inhibiting glucagon secretion, delaying gastric emptying, and reducing appetite [3] - Clinical pre-research indicates that JY54 injection has demonstrated excellent efficacy and safety, with significant potential for weight loss and metabolic improvement [6] Group 2: Market Positioning - The global obesity and metabolic disease prevalence is rising, making weight management therapies a highly active area for pharmaceutical innovation [3] - JY54 injection's mechanism is believed to have advantages over current GLP-1 drugs, potentially leading to better fat reduction while preserving muscle mass [3] - The product's unique molecular structure supports long-acting administration, enhancing patient compliance and laying the groundwork for future combination therapies with GLP-1 [5] Group 3: Strategic Direction - Jiuyuan Gene's pipeline includes both mature products and innovative therapies, creating a clear gradient layout that addresses current market needs while exploring future treatment advancements [6] - The combination of mature products and innovative pipelines is expected to build a resilient long-term development structure in the metabolic disease sector [6] - The acceptance of the IND application reflects Jiuyuan Gene's ongoing investment in innovative drug development and its ambition to enhance its global influence in the metabolic drug innovation field [6]

Core Viewpoint - Semaglutide, a GLP-1 receptor agonist, effectively aids in weight loss by enhancing insulin secretion, suppressing glucagon secretion, delaying gastric emptying, and increasing satiety, leading to reduced appetite and food intake [4][6]. Mechanism of Action - Semaglutide activates specific neurons in the hypothalamus, signaling a feeling of fullness before eating, which is particularly effective in treating obesity [5]. - The appetite-reducing effects of semaglutide occur through three main mechanisms: - Central action: It acts on the hypothalamus to reduce appetite and hunger [6]. - Gastrointestinal action: It slows gastric emptying, increasing feelings of fullness [6]. - Altered food preferences: Patients show a significant decrease in preference and intake of high-fat, fried, or sweet foods [6]. Clinical Efficacy - In clinical trials, patients using semaglutide for 68 weeks lost an average of 15.3 kg, compared to 2.6 kg in the placebo group, with a weight reduction rate of 14.9% versus 2.4% [4]. - The approval of semaglutide for weight management in China is expected to provide a breakthrough solution for overweight and obese patients, enhancing access to effective treatment [13]. Regulatory Approvals - In January 2024, oral semaglutide (Rybelsus) was approved in China for treating type 2 diabetes, marking the first oral GLP-1 receptor agonist approved in the country [9]. - On June 25, 2024, the NMPA approved Wegovy, a semaglutide injection for long-term weight management in China [11]. - The approval of oral semaglutide in the U.S. in December 2025 for weight management and cardiovascular risk reduction signifies a new phase in weight loss medication competition [15][16]. Clinical Trial Data - The OASIS clinical trial demonstrated that daily administration of 25 mg oral semaglutide resulted in an average weight loss of 16.6% over 64 weeks, comparable to the 2.4 mg weekly injection [17]. - Approximately one-third of participants achieved a weight loss of 20% or more, addressing previous concerns about the efficacy of oral GLP-1 treatments [17].

Core Viewpoint - The company emphasizes its commitment to research and innovation, accelerating the secondary development of major products, and systematically advancing ongoing projects while enhancing the output of research results [1] Group 1: Research and Development - The company has received national approval for the project of the raw material and capsules of S-Right Methylphenidate [1] - The company has obtained clinical trial approval for Semaglutide injection [1] - The company is deepening the integration of industry, academia, and medical research, and has been approved for the establishment of the Chongqing Traditional Chinese Medicine New Drug Creation and Intelligent Manufacturing Technology Innovation Center [1]